SYNERGY-NASH
The Phase 3 trials that won approval, and the outcome studies that came afterward on cardiovascular, kidney and sleep-apnea endpoints.
What is SYNERGY-NASH?
Phase 2 of tirzepatide in adults with biopsy-confirmed MASH and significant fibrosis (Loomba 2024 NEJM, PMID 38856224).
The endpoint was histologic — MASH resolution without worsening fibrosis at week 52, which requires a liver biopsy to score. 62% achieved it on 15 mg against 10% on placebo.
SYNERGY-NASH trial deep-dive →
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where SYNERGY-NASH comes up on this site
Connected terms
Other terms under Major trials
Where the evidence lives
- SYNERGY-NASH trial deep-dive
- The full GLP-1 glossary (149 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers